China Medical System Hldgs 

S$2.2
0
-S$0.05-2.22% Friday 01:50

統計

當日最高
2.2
當日最低
2.2
52週高點
2.55
52週低點
2.05
成交量
1,400
平均成交量
-
市值
5.37B
本益比
-
股息殖利率
2.43%
股息
0.05

即將到來

股息

2.43%股息殖利率
May 26
S$0.03
Sep 25
S$0.03
May 25
S$0.02
Sep 24
S$0.03
May 24
S$0.01
10年成長
2.62%
5年成長
-12.41%
3年成長
-22.32%
1年成長
不適用

財報

16Mar預期
Q4 2024
Q2 2025
Q4 2025
0.04
0.05
0.06
0.07
預期EPS
0.052973056016000004
實際EPS
0.04201311339200001

財務

21.68%利潤率
有盈利
2019
2020
2021
2022
2023
2024
2.8B營收
606.11M淨利

其他人也在關注

此清單是根據在 Stock Events 上追蹤 8A8.SG 的使用者自選建立的。這不是投資建議。

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China. The company's products include Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu for the treatment of acute heart failure; Deanxit for the treating mild-to-moderate depression, anxiety, and psychosomatic affections; Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis; Salofalk for treating Ulcerative Colitis and Crohn's disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar. Its products also comprise DanShenTong capsules for treating acne, tonsillitis, otitis externa, boils, carbuncle, traumatic infection, burn infection, mastitis, cellulitis, osteomyelitis, etc.; XiDaKang, a protein hydrolysate oral solution; YiNuoShu for treating respiratory diseases; Ganfule capsules for the treatment of primary cancer of the liver; Imdur for the treatment of coronary heart disease, chronic heart failure, and myocardial infarction, as well as for prevention of vasospasm and mixed angina; and Parlodel tablets for the endocrine and neuro system indications. In addition, the company also offers Elcatonin injection for osteoporosis; YinlianQinggan granules for treating acute hepatitis A and chronic hepatitis B; Lamisil tablets for treating fungal infections on skin and hair; and MOVICOL for treating chronic constipation and faecal impaction. In addition, it is involved in the agriculture and livestock activities. The company was founded in 1995 and is headquartered in North Point, Hong Kong. China Medical System Holdings Limited is a subsidiary of Treasure Sea Limited.
Show more...
執行長
Dr. Kong Lam
員工
6141
國家
開曼群島
ISIN
KYG211081248

上市

0 Comments

分享你的想法

FAQ

China Medical System Hldgs 今天的股價是多少?
8A8.SG 目前價格為 S$2.2 SGD,過去 24 小時下跌了 -2.22%。在圖表上更密切關注 China Medical System Hldgs 股票的表現。
China Medical System Hldgs 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,China Medical System Hldgs 的股票以代號 8A8.SG 進行交易。
China Medical System Hldgs 的市值是多少?
今天 China Medical System Hldgs 的市值為 5.37B
China Medical System Hldgs 下一次財報日期是什麼時候?
China Medical System Hldgs 將於 August 13, 2026 公布下一次財報。
China Medical System Hldgs 上一季度的財報如何?
8A8.SG 上一季度的財報為每股 0.04 SGD,預估為 0.05 SGD,帶來 -20.69% 的驚喜。下一季度的預估財報為每股 不適用 SGD。
China Medical System Hldgs 去年的營收是多少?
China Medical System Hldgs 去年的營收為 2.8BSGD。
China Medical System Hldgs 去年的淨利是多少?
8A8.SG 去年的淨收益為 606.11MSGD。
China Medical System Hldgs 會發放股息嗎?
是的,8A8.SG 的股息每 半年一次 發放一次。每股最新股息為 0.03 SGD。截至今日,股息殖利率(FWD)% 為 2.43%。
China Medical System Hldgs 有多少名員工?
截至 April 25, 2026,公司共有 6,141 名員工。
China Medical System Hldgs 位於哪個產業?
China Medical System Hldgs從事於Health & Wellness產業。
China Medical System Hldgs 何時完成拆股?
China Medical System Hldgs 最近沒有進行任何拆股。
China Medical System Hldgs 的總部在哪裡?
China Medical System Hldgs 的總部位於 開曼群島 的 North Point。